Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

• Status: Unknown status
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cancerologia de Mexico
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+

• BCL-6 negative

• Age < 61 years old

• ECOG 2 or less

• IPI low, low intermediate

• Stage II, III or IV

• Signed Informed Consent

Exclusion Criteria:

• Stage I

• Previous treatment

• Lymphomatous central nervous system involvement

• Heart disease

• Kidney failure (serum creatinine > 2 mg/dl)

• HIV +

• Viral Hepatitis

• Pregnancy